MMR deficiency may lead to a high immunogenicity and then an improvement in anti-PD‐1 efficacy for metastatic colorectal cancer

Nivolumab for advanced squamous cell lung cancer: what are the next steps?

(2015) Ramon Andrade de Mello et al.   LANCET ONCOLOGY

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

(2015) Dung T. Le et al.   NEW ENGLAND JOURNAL OF MEDICINE

New insights into cancer immunoediting and its three component phases—elimination, equilibrium and escape

(2014) Deepak Mittal et al.   CURRENT OPINION IN IMMUNOLOGY

Immunotherapy and lung cancer: current developments and novel targeted therapies

(2014) Duarte Domingues et al.   Immunotherapy

Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial

(2012) Axel Grothey et al.   LANCET

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates

(2010) Julie R. Brahmer et al.   JOURNAL OF CLINICAL ONCOLOGY

Somatic Mutation Profiles of MSI and MSS Colorectal Cancer Identified by Whole Exome Next Generation Sequencing and Bioinformatics Analysis

(2010) Bernd Timmermann et al.   PLoS One

Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria

(2009) J. D. Wolchok et al.   CLINICAL CANCER RESEARCH